Prof. Jianqiu Wu 吴剑秋
Chief Physician, Professor
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for malignant tumors, gastrointestinal endoscopy, lymphoma diagnosis and treatment, and peripheral blood hematopoietic stem cell transplantation.
Dr. Wu holds a doctorate in oncology and serves as Deputy Director of the Medical Oncology Department and Director of the Lymphoma Ward at Jiangsu Cancer Hospital. A 1993 graduate of West China University of Medical Sciences, Dr. Wu completed advanced training at Georgia Health Science University in 2012. Research focuses on standardized lymphoma treatment, hematopoietic stem cell transplantation, and cellular immunotherapy.
Professional roles
- Standing Committee Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Melanoma Professional Committee, China Anti-Cancer Association
- Member, Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Vice Chair, Lymphoma Professional Committee, Jiangsu Anti-Cancer Association
Name order: in Chinese the family name comes first (Wu Jianqiu). Papers usually list the name as Jianqiu Wu or Wu J.
Selected publications
29 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Hematol, 2026 (senior author): A novel prognostic index predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP immunochemotherapy. PubMed 42332295
- Int J Cancer, 2022 (first author): Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study. PubMed 34674396
- Transl Cancer Res, 2021 (senior author): The molecular mechanism of long non-coding ribonucleic acid (lncRNA) RUNX1-IT1 promotes the proliferation and stemness of lung cancer cells. PubMed 35116340
- Clin Biochem, 2019 (first author): The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients. PubMed 30292543
- Chin Med J (Engl), 2018 (first author): Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. PubMed 30058572
- BMC Cancer, 2016 (first author): Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. PubMed 27460571
- Zhonghua Xue Ye Xue Za Zhi, 2014 (first author): [A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma]. PubMed 24857221
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion